10-Q: Tenet Healthcare Reports Q3 2025 Results, Ambulatory Care Drives Growth

Tenet Healthcare Corporation reported a decrease in net income and diluted EPS for the nine months ended September 30, 2025, primarily due to significant gains on facility sales in the prior year, while its Ambulatory Care segment showed strong revenue growth.

Summary

• Net income available to common shareholders was $342 million for the three months ended September 30, 2025, down from $472 million in the same period of 2024, and $1,036 million for the nine months ended September 30, 2025, down from $2,882 million in the same period of 2024.
• Diluted earnings per share (EPS) was $3.86 for Q3 2025, compared to $4.89 for Q3 2024, and $11.28 for 9M 2025, compared to $29.27 for 9M 2024.
• Consolidated net operating revenues increased by 3.2% to $5,289 million for Q3 2025 and by 1.2% to $15,783 million for 9M 2025, compared to the respective prior-year periods.
• The Ambulatory Care segment's net operating revenues grew by 11.9% to $1,275 million for Q3 2025 and by 14.2% to $3,739 million for 9M 2025.
• Hospital Operations segment's net operating revenues increased by 0.7% to $4,014 million for Q3 2025 but decreased by 2.3% to $12,044 million for 9M 2025, primarily due to divestitures in 2024.
• Net cash provided by operating activities increased to $2,809 million for the nine months ended September 30, 2025, from $2,378 million in the prior year.
• The company repurchased $1.188 billion of common stock (7,828 thousand shares) during the nine months ended September 30, 2025, compared to $672 million (5,596 thousand shares) in the same period of 2024.
• The One Big Beautiful Bill Act (OBBBA) was enacted on July 4, 2025, introducing significant changes to the U.S. federal tax code and healthcare policy, with most substantial healthcare provisions taking effect in 2027 and thereafter.

Sentiment

Score: 4

Explanation: While the Ambulatory Care segment shows strong organic and acquisition-driven growth, and same-hospital metrics in Hospital Operations are positive, the overall consolidated financial performance (net income, EPS) is significantly lower year-over-year due to the absence of large asset sale gains from 2024. The company faces substantial regulatory and economic uncertainties, particularly from the OBBBA, which could materially impact future revenues and operations. The increase in share repurchase authorization is a positive signal for shareholder returns, but the overall picture is mixed with significant headwinds.

Positives

• Ambulatory Care segment net operating revenues increased by 11.9% for Q3 2025 and 14.2% for 9M 2025, driven by recent acquisitions and same-facility case growth.
• Same-hospital net operating revenues in the Hospital Operations segment increased by 6.8% for Q3 2025 and 6.3% for 9M 2025, attributed to a more favorable payer mix, higher patient admissions and acuity, growth in Medicaid supplemental revenue, and negotiated commercial rate increases.
• Net cash provided by operating activities increased to $2.809 billion for 9M 2025 from $2.378 billion for 9M 2024.
• The board of directors authorized a $1.500 billion increase to the share repurchase program in July 2025, with $1.688 billion remaining available for future repurchases.
• Litigation and investigation costs showed a benefit of $11 million in Q3 2025, including $28 million from the settlement of two legal matters.
• Hospital Operations salaries, wages, and benefits decreased by 1.0% in Q3 2025, primarily due to lower incentive compensation and reduced contract labor and premium pay costs.
• The company opened the newly constructed Florida Coast Medical Center, a 54-bed acute care hospital in Port St. Lucie, Florida, in September 2025.

Negatives

• Net income available to common shareholders decreased significantly for both the three and nine months ended September 30, 2025, compared to the prior year, primarily due to the absence of substantial gains on facility sales recognized in 2024.
• Diluted EPS decreased to $3.86 for Q3 2025 from $4.89 for Q3 2024, and to $11.28 for 9M 2025 from $29.27 for 9M 2024.
• Hospital Operations segment net operating revenues decreased by 2.3% for 9M 2025, primarily due to the divestiture of hospitals in 2024.
• Total admissions, emergency department visits, and surgeries in the Hospital Operations segment decreased for Q3 2025, mainly reflecting the impact of divestitures.
• Capital expenditures increased to $646 million for 9M 2025 from $601 million for 9M 2024.
• Cash and cash equivalents decreased to $2.975 billion at September 30, 2025, from $3.019 billion at December 31, 2024.
• Income tax payments increased to $329 million for 9M 2025 from $308 million for 9M 2024.
• Supplies expense for the Ambulatory Care segment increased by 18.7% for Q3 2025 and 15.2% for 9M 2025, and as a percentage of net operating revenues, it increased to 26.4% from 24.9% (Q3) and 26.4% from 26.2% (9M).
• Other operating expenses for the Ambulatory Care segment increased by 15.6% for Q3 2025 and 15.6% for 9M 2025, and as a percentage of net operating revenues, it increased to 15.1% from 14.8% (Q3) and 14.9% from 14.6% (9M).

Risks

• Potential delays, reductions, or disruptions in payments from a prolonged government shutdown.
• Uncertainty regarding the scope, implementation timeline, and duration of future tariff actions, which could materially impact the supply chain, capital expenditures, or operating costs.
• The One Big Beautiful Bill Act (OBBBA) is expected to result in material reductions to Medicaid payments, changes to Medicaid supplemental payment programs, and payment delays, with most substantial healthcare provisions taking effect in 2027 and thereafter.
• The Congressional Budget Office anticipates that millions of individuals could lose health insurance between now and 2034 due to OBBBA policy changes, potentially leading to decreased patient volumes, reduced revenues, and an increase in uncompensated care.
• Inability to predict how states will implement OBBBA requirements, leading to variation in financial plans and potential adverse impacts.
• Uncertainty regarding future extensions or modifications of the Affordable Care Act, OBBBA, or other laws affecting the healthcare industry, as well as the current administration's influence on rules and regulations.
• Adverse outcomes in legal actions, including government investigations and class action lawsuits, could be material to results of operations or cash flows.
• Future impairments of long-lived assets and goodwill may occur if facility projections are not met or negative trends impact the future outlook, potentially leading to additional restructuring charges.
• The impact of the demand for, and availability of, qualified medical personnel on compensation costs.
• Overall revenue and cost trends, particularly the timing and magnitude of price changes, and fluctuations in contractual allowances and cost report settlements.
• Managed care contract negotiations, settlements, or terminations and payer consolidations.
• Trends in patient accounts receivable collectability and associated implicit price concessions.
• The impact of cybersecurity incidents on operations, including those targeting vendors, and other unanticipated information technology outages.
• Fluctuations in interest rates, although mitigated for long-term debt by fixed rates.
• Levels of malpractice insurance expense and settlement trends.
• Losses, costs, and insurance recoveries related to natural disasters and weather-related occurrences.
• The potential emergence and effects of future pandemics, epidemics, or outbreaks of infectious diseases on operations, financial condition, and liquidity.
• Changes in occupancy levels and patient volumes due to various factors such as government healthcare funding, general economic conditions, physician recruitment, advances in technology, local competitors, and changing consumer behavior.

Future Outlook

The company anticipates capital expenditures for the year ending December 31, 2025, to total approximately $875 million to $975 million. It expects to engage in additional capital markets, bank credit, and other financing activities depending on needs and available alternatives, believing existing debt agreements provide flexibility for future secured or unsecured borrowings. The company believes existing cash, credit facility availability, and anticipated operating cash flows are adequate to meet current cash needs, planned capital expenditures, debt payments, and other presently known operating needs. Long-term liquidity for debt service and other purposes is dependent on the amount of cash provided by operating activities and, subject to favorable market and other conditions, the successful completion of future borrowings and potential refinancings.

Management Comments

• We continue to focus on opportunities to expand our Ambulatory Care segment through acquisitions, organic growth in our physician relationships and service lines, construction of new outpatient centers and strategic partnerships.
• We believe USPI's ASCs and surgical hospitals offer many advantages to patients and physicians, including greater affordability, predictability, flexibility and convenience.
• We believe the volume and complexity of surgical cases performed in an outpatient setting will continue to increase over time.
• Historically, our outpatient services have generated significantly higher margins for us than inpatient services.
• We remain committed to better positioning our hospitals and competing more effectively in the ever-evolving healthcare environment by focusing on driving performance through operational effectiveness, investing in our physician enterprise, particularly our specialist network, enhancing patient and physician satisfaction, growing our higher-demand and higher-acuity clinical service lines, expanding patient and physician access, and optimizing our portfolio of assets.
• We believe our efforts in these areas improve the quality of care we deliver and enhance growth.
• When used responsibly, we believe AI has the potential to enhance our business processes and support efficient delivery of high-quality care.
• We believe that emphasis on higher-demand clinical service lines, focus on expanding our ambulatory care business, cultivation of our culture of service, participation in Medicare Advantage health plans and contracting strategies that create shared value with payers should help us grow our patient volumes over time.
• We believe that our capital structure helps to minimize the near-term impact of increased interest rates, and the staggered maturities of our debt allow us to retire or refinance our debt over time.

Industry Context

The healthcare industry faces ongoing challenges from staffing and labor trends, supply chain operational issues, general economic and geopolitical conditions, and potential changes in federal and state healthcare laws, regulations, funding policies, and reimbursement practices. The recently enacted One Big Beautiful Bill Act (OBBBA) is expected to have far-reaching implications, including new Medicaid work requirements, caps on state-directed payments, and stricter eligibility checks, potentially leading to millions losing health insurance by 2034. Regulatory updates from CMS include a projected 4.4% average increase in Medicare operating payments for proprietary hospitals in FFY 2026 and a 2.4% average increase in Medicare FFS ASC payments for CY 2026, alongside an increased offset for 340B-acquired drug payment policy. The company is also exploring the adoption of AI-enabled tools to enhance business processes and support efficient delivery of care.

Management Changes

Corporate Governance

Legal Proceedings

• Litigation and investigation costs (benefit) totaled $(11) million for the three months ended September 30, 2025, and $34 million for the nine months ended September 30, 2025.
• During the three months ended September 30, 2025, the company received proceeds of $28 million from the settlement of two legal matters.
• The company operates in a highly regulated and litigious industry and is subject to numerous investigations by various governmental agencies, as well as class action lawsuits, employment-related claims, commercial litigation, and other legal actions.
• Accruals for estimated losses relating to claims and lawsuits are recorded when a loss is probable and reasonably estimable, with significant judgment required in these determinations.

Related Party Transactions

• The contract with Catholic Health Initiatives (CHI), now known as CommonSpirit Health and the minority interest holder in the Conifer Health Solutions, LLC joint venture, represents the majority of the fixed-fee revenue related to remaining performance obligations.
• The contract term with CHI is scheduled to end on December 31, 2032.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and EPS (primarily due to non-recurring gains in the prior year), the increased share repurchase program, and the company's strategic focus on Ambulatory Care growth.
• Employees are affected by restructuring charges ($33 million for 9M 2025, including $5 million of employee severance costs), the transition of administrative functions to the Global Business Center in the Philippines, and annual merit increases.
• Patients are impacted by the opening of new facilities (e.g., Florida Coast Medical Center), the company's enhanced focus on customer care experience, and potential changes in health insurance coverage and Medicaid eligibility due to the OBBBA.
• Suppliers are affected by the company's continued focus on cost-efficiency measures, including product standardization, contract management, improved utilization, and bulk purchases.
• Creditors benefit from the company's capital structure, which includes fixed-rate long-term debt with staggered maturities, helping to minimize the near-term impact of increased interest rates. The company was in compliance with all debt covenants at September 30, 2025.

Next Steps

• Evaluate the timing of adoption and impact of ASU 2025-05 on condensed consolidated financial statements and related disclosures.
• Continue to focus on expanding the Ambulatory Care segment through acquisitions, organic growth in physician relationships and service lines, construction of new outpatient centers, and strategic partnerships.
• Drive growth in the Hospital Operations segment through operational effectiveness, investment in the physician enterprise, enhancing patient and physician satisfaction, growing higher-demand clinical service lines, expanding patient and physician access, and optimizing the portfolio of assets.
• Improve the customer care experience by broadening access to convenient services, expanding service lines, offering greater affordability and predictability, improving the culture of service, and offering tailored health programs and education.
• Pursue new opportunities to enhance efficiency, including further integration of enterprise-wide centralized support functions, outsourcing additional functions unrelated to direct patient care, and reducing clinical and vendor contract variation.
• Monitor developments in international trade policy, including those related to tariffs, and the potential impact of a prolonged government shutdown on operations.
• States are awaiting additional guidance from federal agencies on several provisions of the OBBBA and are likely to reevaluate their financial plans for 2026 and beyond.
• A national search is ongoing to identify a successor for R. Scott Ramsey, Senior Vice President & Controller, who plans to retire effective March 31, 2026, with the successor to be mentored and onboarded by Mr. Ramsey.
• Engage in additional capital markets, bank credit, and other financing activities depending on needs and financing alternatives available.

Key Dates

Recommendation

The company's core operations show mixed results, with strong growth in the Ambulatory Care segment and positive same-hospital trends in Hospital Operations, offset by overall volume declines in Hospital Operations due to divestitures. The significant drop in net income and EPS is primarily due to the non-recurrence of substantial asset sale gains from the prior year, which distorts year-over-year comparisons of underlying operational performance. While the increased share repurchase program is a positive for shareholder returns, the regulatory environment, particularly the OBBBA, introduces considerable uncertainty and potential headwinds for future revenues and patient volumes. Given the strong performance in Ambulatory Care and strategic initiatives, but also the significant regulatory risks and the non-recurring nature of prior-year gains, a 'Hold' recommendation is appropriate as investors await clearer impacts of the OBBBA and continued execution on strategic growth.

Keywords

Healthcare, Ambulatory Care, Hospital Operations, USPI, SEC Filing, 10-Q, Financial Results, Earnings, Revenue, Net Income, EPS, Capital Expenditures, Share Repurchase, Debt, Medicaid, Medicare, OBBBA, Government Programs, Risk Factors, Management Changes, Tenet Healthcare